ClinicalTrials.gov
ClinicalTrials.gov Menu

Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00620893
Recruitment Status : Completed
First Posted : February 22, 2008
Last Update Posted : September 21, 2009
Sponsor:
Information provided by:
Bp Consulting, Inc

Brief Summary:
This study will evaluate and compare 2 artificial tears in their ability to reduce post LASIK dry eye signs and symptoms. The secondary endpoint of this study is to evaluate refractive regression in these patients. The 'Refractive Outcome' data point will be defined as the difference between the post-op spherical equivalent (SE) and the pre-op targeted SE.

Condition or disease Intervention/treatment Phase
Dry Eye Syndromes Drug: PEG- 400 based artificial tear Drug: Systane Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : February 2008
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009


Arm Intervention/treatment
Active Comparator: 1
1. PEG-400 based artificial tear
Drug: PEG- 400 based artificial tear
Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily

Active Comparator: 2
2. Systane
Drug: Systane
Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily




Primary Outcome Measures :
  1. dry eye signs [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. refractive regression [ Time Frame: 9 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients ranging from normal to mild dry eye per physician assessment
  • BCVA of 20/20
  • Moderate to high myopia (-3 D to -10D of sphere)
  • Patients who are scheduled to under go myopic bilateral LASIK with VISX laser

Exclusion Criteria:

  • Patients currently using topical cyclosporine
  • Patients currently using Systane
  • Patients currently using an oil-based artificial tear such as Soothe or Endura
  • Any post-op epithelial defects or flap complications requiring further procedures (relifting, scraping, stretching etc.)
  • DLK greater than stage 1 or infectious keratitis post-operatively
  • Any uncontrolled systemic disease that may confound the results of this trial (Diabetes, Lupus, Rheumatoid Arthritis etc.)
  • Anisometropia greater than 1D

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00620893


Locations
United States, New York
Weill Cornell Medical Center
New York, New York, United States, 10021
Sponsors and Collaborators
Bp Consulting, Inc
Investigators
Principal Investigator: Christopher Starr, MD Weill Medical College of Cornell University

Responsible Party: Dr. Christopher Starr, Weill Cornell Medical Center
ClinicalTrials.gov Identifier: NCT00620893     History of Changes
Other Study ID Numbers: 5339
First Posted: February 22, 2008    Key Record Dates
Last Update Posted: September 21, 2009
Last Verified: September 2009

Keywords provided by Bp Consulting, Inc:
Dry eye signs and symptoms
refractive regression

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Lubricant Eye Drops
Ophthalmic Solutions
Pharmaceutical Solutions